Status: Recruiting
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Updated: Aug 26, 2024Locations: 1
Eligibility criteria
Male or female patient ≥18 years old; [+8]
Uncontrolled or severe diarrhea with significant dehydration; [+13]